Analysis of clinicopathological and molecular characteristics of EBV-associated gastric cancer Authors: Li Wu, Shuai Luo, Lu Zhao, Anying Long, Yao Li, Jinjing Wang Published: 2025 ABSTRACT AbstractObjectiveThis study aims to explore the clinicopathological and molecular traits of Epstein-Barr virus-associated gastric cancer (EBV-GC).MethodsA retrospective analysis was performed on the clinicopathological features, immunophenotype, and molecular characteristics of seven EBV-GC cases utilizing next-generation sequencing (NGS) technology.ResultsAmong the seven cases, six were male and one was female, aged from 24 to 76 years (mean age: 56 years). Tumor sizes varied between 10 and 100 mm (mean size: 54.2 mm). The tumors were mainly located in the upper and middle regions of the stomach, predominantly exhibiting an ulcerative appearance. Numerous cases were linked with gastric carcinoma with lymphoid stroma. About half of the cases were identified as diffuse type according to the Lauren classification. All cases were in the early stage, with lymph node metastasis being uncommon. Immunophenotyping demonstrated positive Epstein-Barr virus-encoded RNA, common overexpression of programmed death-ligand one, and presence of tumor-infiltrating lymphocytes. Human epidermal growth factor receptor 2 (HER2) and microsatellite instability were negative. The molecular characteristics frequently included PIK3CA and ARID1A mutations, whereas TP53, HER2, EGFR mutations, and deficient mismatch repair were absent.ConclusionEBV-GC is characterized by distinct clinicopathological and molecular features. Pathological examination, immunophenotyping, and NGS provide significant value for diagnosis and therapeutic direction.Keywords: Clinicopathological features, Epstein-Barr virus-associated gastric cancer, Immunophenotype, Molecular characteristics, Next-generation sequencing Background Based on the global statistics issued by the International Agency for Research on Cancer (IARC) in 2020, gastric cancer (GC) is positioned 5th in terms of incidence and 4th in mortality among malignant neoplasms [1]. In 2014, The Cancer Genome Atlas (TCGA) cohort utilized various technologies to categorize heterogeneous GC into four molecular subtypes: Epstein-Barr virus-associated gastric cancer (EBV-GC), microsatellite instability (MSI), chromosomal instability (CIN), and genomically stable (GS) tumors [2]. EBV-GC comprises about 8% of GCs [3]. Burke et al., in 1990, initially identified EBV-GC as tumor cells (TCs) infected with Epstein-Barr virus (EBV) through the analysis of formalin-fixed paraffin-embedded (FFPE) specimens of undifferentiated lymphoepithelioma-like gastric carcinoma using polymerase chain reaction (PCR) [4]. EBV-associated malignancies exhibit morphological similarities to nasopharyngeal lymphoepithelioma (LE) and are also termed LE-like carcinomas. The majority of EBV-associated gastric cancers histologically align with gastric carcinoma with lymphoid stroma (GCLS), as described by Watanabe et al. [5]. Given the rarity of this tumor and its distinctive clinicopathological characteristics, this study presents seven cases of EBV-GC, elaborating on their clinicopathological and molecular features, with the aim of raising awareness among clinicians and pathologists. Methodologies and materials Clinical data This study protocol received approval from the Institutional Review Board of the Affiliated Hospital of Zunyi Medical University. Seven patients diagnosed with EBV-GC at the Department of Pathology, Affiliated Hospital of Zunyi Medical University, between January 1, 2020, and February 5, 2024, were included in this study. The criteria for inclusion were: (1) primary GC confirmed through surgical or endoscopic biopsy pathology; (2) positive detection of EBV in GC cells using EBV-encoded small RNA in situ hybridization (EBER-ISH). The exclusion criterion was the presence of simultaneous active primary tumors at other locations. Methodology Diagnostic criteria for EBV subtyping in GC Tissue sections were analyzed by pathologists, and the EBER-ISH detection results were used as the diagnostic gold standard. The diagnostic criteria were defined as EBER positive when there was a uniform and diffuse positive signal in the nucleus of tumor cells and no positive expression in the surrounding non-tumor cells. Pathological analysis The staging of the tumor using the TNM (Tumor, Node, Metastasis) system was conducted following the 8th edition guidelines of the American Joint Committee on Cancer (AJCC) [6]. The percentage of tumor-infiltrating lymphocytes (TILs) was assessed on whole slides stained with hematoxylin and eosin (H&E). The expression of programmed death-ligand 1 (PD-L1) and human epidermal growth factor receptor 2 (HER-2), along with the determination of MSI/microsatellite stable (MSS) status, were evaluated through immunohistochemistry (IHC). MSI, indicative of deficient mismatch repair (D-MMR) in TCs, is characterized by defects in any of the mismatch repair genes: MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), PMS1 homolog 2 (PMS2), or MutS homolog 6 (MSH6). FFPE tissue sections were 4 μm thick and used for H&E staining, IHC and EBER-ISH detection. H&E staining The hematoxylin-iodine staining is performed using an automated staining machine. After section processing through xylene dewaxing and gradient ethanol dehydration, the sections undergo 1–5 min of hematoxylin staining. Following moderate ethanol hydrolysis for differentiation, the sections are rinsed with tap water to achieve bluing. Subsequently, eosin staining is applied for 30 s–5 min to stain the cytoplasm. Finally, the sections are dehydrated using gradient ethanol, mounted in xylene for transparency, and sealed with neutral formaldehyde resin. Immunohistochemistry (IHC) The detection was performed using the LEICA BOND automated immunohistochemical staining system and EnVision TM method. After dewaxing and hydration of sections, endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Following antigen retrieval, the sections were incubated with primary antibodies at room temperature for 30–60 min: anti-PD-L1 rabbit monoclonal antibody(SP263), anti-HER-2 rabbit monoclonal antibody (EP1045Y), anti-MLH1 mouse monoclonal antibody (G168-15), anti-MSH2 mouse monoclonal antibody (G219-1129), anti-MSH6 mouse monoclonal antibody (EP49), and anti-PMS2 rabbit monoclonal antibody (A16-4). After buffer washing, the EnVision TM method was applied using DAB as the chromogenic substrate, with color development time monitored under a microscope. Finally, cells were stained with hematoxylin for nuclear re-dyeing, followed by gradient ethanol dehydration, xylene clearing, and slide mounting. EBER in situ hybridization (EBER-ISH) The EBER-ISH protocol follows the standard procedures specified in the reagent kit. After processing of sections through baking, dewaxing, waterization, and proteinase K digestion, the samples are incubated with EBER-specific probes in a 55 °C humid chamber for 60–90 min, followed by a 2–14 h extension at 37 °C in an in situ hybridization instrument. Post-hybridization, the sections are rinsed with 48 °C PBS to remove non-specific binding. Subsequent incubation steps involve sequentially adding reagent A (mouse anti-catharidine hydrochloride antibody), reagent B (rabbit anti-mouse antibody), and reagent C (Lycorine peroxidase labeled goat anti rabbit antibody), with each step followed by PBS rinsing. DAB staining is performed, followed by hematoxylin re staining, gradient ethanol dehydration, xylene clearing, and final slide mounting. Molecular detection Next-generation sequencing (NGS) was employed on FFPE samples [7]. From representative paraffin-embedded tumor tissues (FFPE) of 7 EBV-GC patients, pathologists selected tumor regions under a microscope and performed macroscopic dissection with a thickness of 5 μm. Blades were replaced or cleaned during each sectioning process to prevent cross-contamination. DNA extraction was completed using nucleic acid extraction and purification reagents (Shanghai Sidi Biomedical Technology Co., Ltd.). Gene detection utilized the Human Tumor 733 Gene Mutation Combined Detection Kit (Reversible Terminal Ligation Sequencing, Shanghai Sidi Biomedical Technology Co., Ltd.) to construct libraries. Library concentration was measured using a Qubit 4.0 fluorescence quantifier, and the library was quantified again after hybridization capture via PCR. Sequencing was performed on the NextSeq 550 Dx platform, with sequencing data analyzed through the TiNAiLab Tumor Genomics Data Analysis System (Shanghai Sidi Biomedical Technology Co., Ltd.) to generate mutation analysis reports. Follow-up methods Seven patients diagnosed with EBV-GC were followed up until July 2, 2024. The main follow-up method involved telephone contact. Results Clinical features As illustrated in Tables 1 and 2, the mean age of the seven EBV-GC patients was 57 years. EBV-GC was predominantly detected in male patients (85.7%), with its incidence in the upper or middle stomach being nearly six times that in the lower stomach (85.7% vs. 14.3%). The most prevalent macroscopic type was ulcerative (85.7%). Among the 7 patients with EBV-GC, tumor invasion was distributed across T1 (14.3%), T2 (71.4%), and T3 (14.3%) stages, with no T4 cases (0%), indicating that invasion depths were predominantly at T2–T3 stages, while early lesions (T1) were uncommon. Lymph node metastasis was less frequent (42.9%). and TNM stages I and II were predominant (100%), with stages III and IV being rare (0%). Conversely, vascular invasion was observed more frequently (71.4%). Table 1Basic clinicopathological features of 7 EBV-GC patientsCase1234567Date of diagnosis2023-022022-112022-082020-032023-122022-012023-05GenderFemaleMaleMaleMaleMaleMaleMaleAge (years)24545664597666LocationGastric fundusGastric bodyGastric angularisGastric bodyJunction of gastric fundus and bodyGreater curvature at the junction of the antrum and bodyGastric body and cardiaMaximum tumor diameter (mm)754550100103070Macroscopic typePolypoid typeUlcerative typeUlcerative typeUlcerative typeUlcerative typeUlcerative typeUlcerative typeDepth of tumor invasionInvasion to muscularis mucosae (M3)Invasion through the entire gastric wall without penetrating the serosaInvasion through the entire gastric wall without penetrating the serosaInvasion into the subserosal connective tissueInvasion through the entire gastric wall without penetrating the serosaInvasion through the entire gastric wall without penetrating the serosaSubserosaLymph node metastasis0/150/124/190/8-0/276/56Lymphovascular invasion0(+)(+)(+)0(+)(+)TNM stageT1aN0M0T2N0M0T2N2M0T3N0M0T2N2M0T2N0M0T2N2M0Lauren classificationMixed typeIndeterminate typeDiffuse typeDiffuse typeIndeterminate typeIndeterminate typeDiffuse typeWHO classification/GCLSGCLSGCLSPoorly cohesive typePoorly cohesive typeGCLSGCLSGCLSEBER positivity rate80%90%90%90%80%70%80%HER-2 status0000001+MSI/MSS statusMSSMSSMSSMSSMSSMSSMSSPD-L1 (CPS)301560Negative5510PD-L1 (TPS)40%30%50%Negative10%5%70%Intratumoral TILs30%50%30%20%20%20%50%Treatment regimenGastrectomy for gastric cancerGastrectomy for gastric cancer + oral chemotherapy for six monthsGastrectomy for gastric cancer + multiple cycles of chemotherapyPalliative surgical resection of a large gastric tumor (Billroth II anastomosis); patient refused gastrectomy for gastric cancer after condition stabilizedGastrectomy for gastric cancer + eight cycles of chemotherapyGastrectomy for gastric cancer + nine cycles of chemotherapyGastrectomy for gastric cancerPrognosisAlive, no recurrence or metastasis found on follow-upAlive, no recurrence or metastasis found on follow-upAlive, no recurrence or metastasis found on follow-upDeceased, died six months after follow-up, the specific cause of death was unknownAlive, no recurrence or metastasis found on follow-upAlive, no recurrence or metastasis found on follow-upAlive, no follow-up examination was performed, and no specific discomfort was reportedOverall survival (months)172023673014 Basic clinicopathological features of 7 EBV-GC patients Table 2.Patient characteristics (n = 7)VariableValueAge (years)Median (range)59 (24–76)Sex, n (%)Male6 (85.7%)Female1 (14.3%)LocationUpper and middle stomach6 (85.7%)Lower stomach1( 14.3%)Macroscopic typePolypoid type1 (14.3%)Ulcerative type6 (85.7%)Depth of invasionT1/T2/T37 (100%)T40 (0%)Lymph node metastasisN04 (57.1%)N1 – N33 (42.9%)Lymphovascular invasionNegative2 (28.6%)Positive5 (71.4%)TNM stageI – II7 (100%)III – IV0(0%)Lauren classificationDiffuse type3 (42.9%)Indeterminate type3 (42.9%)Mixed type1 (14.2%)WHO classification/GCLSGCLS5 (71.4%)Poorly cohesive type2 (28.6%)Intratumoral TILs≥ 27.5%4 (57.1%)≤ 27.5%3 (42.9%)PD-L1 (CPS)Negative1 (14.3%)Positive6 (85.7%)PD-L1 (TPS)Negative1 (14.3%)Positive6 (85.7%)EBER positivityNegative0 (0%)Positive7 (100.0%)HER-2Negative7 (100.0%)Positive0 (0%)MSI/MSSMSS7 (100.0%)MSI0 (0%) .Patient characteristics (n = 7) Clinicopathological features IHC and ISH The presence of lymphoid stroma was identified in 71.4% of patients, classifying them as having GCLS. According to the Lauren classification, 42.9% of patients were categorized as diffuse type. An assessment of intratumoral TILs indicated that 57.1% of patients had TILs ≥ 27.5% (The reason why 27.5% was adopted as the dividing point between high and low TILs in this study is that this threshold was derived from the median of the population reported by Kang et al. in the EBV-GC cohort study [8], which was reused and verified in their subsequent independent cohort studies [9]).Furthermore, PD-L1 expression in tumor cells (TCs) was detected in 85.7% of cases. PD-L1 expression in both TCs and immune cells (ICs) was also observed in 85.7% of cases, yielding a combined positive score (CPS) based on dual TC and IC positivity. PD-L1 IHC was performed using the rabbit monoclonal antibody SP263, with CPS calculated as (number of PD-L1–positive TCs + PD-L1–positive ICs) ÷ total number of tumor cells × 100. The tumor proportion score (TPS) was simultaneously assessed as the percentage of PD-L1–positive TCs among total tumor cells, with CPS ≥ 1 considered positive according to established criteria. TPS results were consistent with CPS. ISH confirmed EBV positivity in all cases (100.0%). IHC revealed no expression of HER2 and no deficiencies in mismatch repair genes (MMR). Gross features of EBV-GC Among the seven cases, six (85.7%) were identified as ulcerative type and one (14.3%) as polypoid type. The ulcerative type, depicted in Fig. 1, exhibited a well-defined ulcer with raised edges encircling the tumor. The cut surface of the tumor was grayish-white, solid, and of medium consistency, with no signs of hemorrhage or necrosis. Of the seven cases, five (71.4%) were located in the middle and upper regions of the stomach, while two (28.6%) were situated in the lower region. Surgical specimen of EBV-GC. The tumor is located on the greater curvature of the gastric body (indicated by arrow), measuring approximately 4.5 × 4 × 2 cm. It appears as an ulcerative type with well-defined boundaries and elevated margins surrounding the ulcer Typical endoscopic features of EBV-GC Of the seven cases, six (85.7%) were classified as ulcerative type, and one (14.3%) as polypoid type. Additionally, lymphoid stroma was present in five cases (71.4%). The invasion of EBV into the deep submucosa led to the presence of prominent lymphoid tissue (lymphoid stroma) surrounding the cancer tissue, resulting in characteristic submucosal tumor-like protrusions, as depicted in Fig. 2. Typical endoscopic images of EBV-GC. Image A depicts a tumor situated at the junction of the gastric fundus and body, while image B shows a tumor in the gastric body. Both tumors are of the ulcerative type. EBV invasion into the deep submucosa results in submucosal tumor-like protrusions, characterized by prominent lymphoid tissue (lymphoid stroma) encircling the cancerous tissue Microscope characteristics Of the seven cases, five (71.4%) were associated with lymphoid stroma, with tumors predominantly consisting of small cancer nests and abundant lymphoid stroma (Fig. 3). The cancer cells primarily displayed thin trabeculae, microcystic, and primitive tubular arrangements. Additionally, the tumors could be composed of well-differentiated tubular adenocarcinoma and lymphoid stroma, as illustrated in Fig. 4. Microscopic morphology of EBV-GC. The tumor comprises small cancer nests and abundant lymphoid stroma (H&E staining, original magnification ×40) Microscopic morphology of EBV-GC. The tumor comprises well-formed tubular adenocarcinoma foci and lymphoid stroma (H&E staining, original magnification ×200) ISH EBV was identified in all cases (100%) through EBER-ISH (Fig. 5). The EBER signals were uniformly and diffusely observed in the nuclei of TCs within these lesions, while no EBER-positive signals were found in the interstitial infiltrating lymphocytes. The EBER signals were evident in the cancerous regions, whereas no EBER positivity was detected in non-cancerous mucosal epithelial cells. Histological characteristics of EBV-GC. As illustrated in image A(HE) and B(EBER/ISH), EBER-ISH reveals brown EBER signals in the nuclei of cancer cells (indicated by red arrows), while the stromal infiltrating lymphocytes are EBER-negative. Image C(HE) and D(EBER/ISH) shows brown EBER signals in the cancerous area (indicated by red arrows), whereas the surrounding non-cancerous mucosal epithelial cells are EBER-negative (original magnification ×200) Expression of PD-L1 In the seven cases analyzed, PD-L1 expression(Figure 6) was identified in TCs in six cases (85.7%). Likewise, PD-L1 expression was concurrently observed in both TCs and ICs in six cases (85.7%). The cell membranes and ICs of EBV-GC were positively stained using the SP263 antibody. In certain cases, the quantity of stained TCs exceeded that of ICs, whereas in other cases, the quantity of stained ICs surpassed that of TCs. Gene mutation analysis The gene mutation results are presented in Table 3, while Table 4 outlines the gene mutation spectrum for seven patients. Of these patients, six (85.7%) exhibited at least one somatic gene alteration. The most frequently observed gene mutations included PIK3CA (42.8%) and ARID1A (42.8%), followed by PTEN (14.3%), SMAD4 (14.3%), RAD50 (14.3%), and NRAS (14.3%). Notably, PTEN and SMAD4 function as tumor suppressor genes, whereas RAD50 is involved in homologous recombination (HR). There were no mutations were detected in other prevalent GC genes or significant drug targets such as TP53, ERBB2, and EGFR. Nonetheless, since PIK3CA, NRAS, and PTEN are recognized as FDA-approved target genes, five out of seven patients (71.4%) in this study harbored mutations in FDA-approved target genes. Table 3Gene mutationsCaseDate of diagnosisGene mutationTumor Mutational Burden (Muts/Mb)Microsatellite Stability StatusEBV12023-02 PTEN 137.21MSSPositive22022-11ARID1A8.32MSSPositive32022-08PIK3CA (p.E545K,Exon10), RAD50, SMAD4, RIT14.16MSSPositive42020-03PIK3CA (p.E545K,Exon10), BCOR, SMAD4, CDH1, CTNNB1PBRM15.2MSSPositive52023-12None0MSSPositive62022-01PIK3CA (p.E545K,Exon10), ARID1A1.04MSSPositive72023-05ARID1A, NRAS, PIK3R15.2MSSPositive Gene mutations PIK3CA (p.E545K, Exon10), RAD50, SMAD4, RIT1 PIK3CA (p.E545K, Exon10), BCOR, SMAD4, CDH1, CTNNB1 PBRM1 PIK3CA (p.E545K, Exon10), ARID1A Table 4Important gene mutations detected by NGSOncogenesN = 7PIK3CA3 (42.8%)NRAS1 (14.3%)ERBB20 (0.0%)EGFR0 (0.0%)Tumor suppressor genesARID1A3 (42.8%)SMAD41 (14.3%)PTEN1 (14.3%)TP530 (0.0%)HR genesRAD501 (14.3%)EBV detectionPositive7 (100%)D-MMRMLH10 (0.0%)MSH20 (0.0%)PMS20 (0.0%)MSH60 (0.0%)Tumor mutational burden≥ 10 Muts/Mb1 (14.3%) Important gene mutations detected by NGS Treatment and follow-up One patient, due to severe abdominal contamination from posterior wall perforation of a large tumor upon admission, underwent palliative tumor resection with Billroth II anastomosis and later declined gastrectomy for gastric cancer after stabilization. The remaining six patients received gastrectomy for gastric cancer. Follow-up results were documented for all patients. Five patients remained disease-free during a follow-up period ranging from 7 to 30 months. One patient, with a large tumor (100 mm) and posterior wall perforation, died six months post follow-up, with the specific cause of death unspecified. Another patient, followed up for 13 months, did not return for gastroscopy and enhanced CT examination but reported no specific discomfort. Discussion It is well-documented that EBV-GC predominantly affects male patients, with a notably younger age of onset. These tumors are frequently located in the upper and middle regions of the stomach, primarily presenting as ulcerative lesions. EBV-GC exhibits a significantly higher incidence of early-stage tumors characterized by submucosal infiltration. Lymph node metastasis is uncommon, and GCLS is often associated. A substantial proportion of cases exhibit diffuse-type histology. Microscopically, EBV-GC is characterized by sparse or dense lymphocytic infiltration throughout the tumor area, with minimal stromal fibrosis. The sparse carcinoma cell nests are arranged in thin trabeculae, small clefts, or primitive tubules, occasionally accompanied by well-differentiated adenocarcinoma areas, particularly in the mucosa [5]. EBER ISH typically reveals diffuse and uniform positivity in tumor tissues and dysplastic epithelium, while remaining negative in stromal infiltrating lymphocytes and adjacent normal gastric mucosa [10]. These features constitute the key diagnostic criteria for EBV-GC. Differential Diagnosis: (1) Poorly differentiated carcinoma with lymphoid stromal reaction: Typically, these patients have a history of radiotherapy or chemotherapy, and EBER ISH results are negative. (2) Metastatic carcinoma with lymphoid stroma: This carcinoma commonly originates from the nasopharynx. Histologically, it often displays a nested pattern without glandular structures, lacks transitional areas between gastric mucosa and invasive carcinoma, and exhibits negative IHC staining for cytokeratin 7. (3) Microsatellite instability-high gastric cancer: Although its histology resembles that of EBV-GC, IHC reveals a loss of MMR protein expression, and EBER ISH is negative. In contrast, EBER ISH is positive in EBV-GC [10]. This study reveals that the mean age of onset for EBV-GC is significantly lower compared to EBV-negative patients (57 years vs. 68.9 years) [11]. EBV-GC predominantly affects males (85.7%), aligning with most research findings. Etiologically, EBV infection typically occurs in early childhood. While the cofactors for EBV-GC remain unidentified, the higher prevalence in males may be linked to lifestyle factors more common among men [12]. The onset age correlates with the exposure age to these cofactors. In this study, EBV-GC was more prevalent in the upper and middle regions of the stomach (85.7%), consistent with the previously reported predominance in these regions (77%) [12]. This is attributed to the higher frequency of EBV-GC in the area between the fundic and pyloric glands, with the middle region shifting proximally as age increases [12]. The majority of EBV-GC cases are observed to present as ulcerative type (85.7%), aligning with previous findings that highlight the predominant manifestation of EBV-GC as ulcerative type (86.2%) [11]. Notably, a polypoid EBV-GC case measuring 75 mm in diameter was documented, showcasing the minimal invasion depth (muscularis mucosae) among the cases analyzed in this study. This observation parallels a previously reported 4.0 cm polypoid EBV-GC case by Horiguchi et al. [13], which also demonstrated invasion confined to the mucosal layer. Furthermore, it remains to be verified through larger cohort studies whether polypoid EBV-GC typically exhibits shallower invasion depths in comparison to the ulcerative type. The 8th edition of the AJCC TNM staging system has introduced clinical staging. The staging committee identified that patients with cT4bNxM0 had a markedly poor prognosis, aligning with most clinical observations. As a result, this subgroup has been categorized as stage IV in the new clinical staging criteria, unlike in pathological staging, where it is designated as stage III [6]. Consequently, this study differentiated between T1, T2, T3, and T4 stages. The findings indicated that EBV-GC exhibited shallower invasion depths, predominantly within T1, T2, and T3 stages (85.7%), with a lower incidence of lymph node metastasis (42.9%). These results are comparable to the report by Yanagi et al., which documented EBV-GC at T1, T2, and T3 stages (87.5%) and lymph node metastasis at 37.3% [11]. In the current study, all patients were within T1, T2, or T3 stages. Due to the shallower invasion depth and reduced lymph node metastasis, earlier surgical interventions were facilitated, thereby enhancing survival rates. Among the seven patients, six survived, with five (71.4%) achieving disease-free survival ranging from 7 to 30 months at the latest follow-up, while one patient reported no specific discomfort at 13 months follow-up but did not return for further examination. Conversely, one patient at T3 stage succumbed six months post-follow-up, with an overall survival of just six months. This outcome might be attributable to tumor perforation on the posterior wall upon admission, resulting in severe abdominal contamination and necessitating emergency “palliative surgical resection of a giant gastric body tumor (Billroth II anastomosis)”. Despite stabilization, the patient refused subsequent gastrectomy for GC, and vascular invasion was observed. Moreover, previous studies have even suggested the feasibility of endoscopic treatment for EBV-GC, given the lower frequency of lymph node metastasis reported in early stages, despite poor differentiation [3]. The incidence of lymphovascular invasion in EBV-GC (71.4%) observed in this study is markedly higher than the previously reported rate of 5.4% [14]. This variation could be attributed to the elevated frequency of PIK3CA mutations (42.8%) identified here, compared to the 25.0% noted in earlier reports [14]. Importantly, all three instances (42.8%) of PIK3CA exon 10 E545K mutations in this research were associated with positive lymphovascular invasion. The three most frequently reported PIK3CA mutation hotspots (E542K, E545K, and H1047R) are known to enhance lipid kinase activity, subsequently activating the downstream Akt signaling pathway [15]. It is well-documented that the activation of the PI3K-AKT-mTOR pathway facilitates angiogenesis [16]. Ji-Won Kim et al. documented a cohort where PIK3CA mutations correlated with more aggressive vascular invasion compared to PIK3CA wild-type cases, while no other invasive characteristics differed between the PIK3CA mutant and wild-type groups [17]. Consequently, the increased lymphovascular invasion rate in this study may primarily be due to the high occurrence of PIK3CA exon 10 E545K mutations. Furthermore, the limited sample size of this study may have amplified the observed increase in this ratio. It should be noted that the exon numbering for PIK3CA has been revised. Since exon 1 is completely UTR and non-coding, many prior studies excluded it from their numbering. As a result, those studies labeled E545 and H1047 mutations as occurring in exon nine and exon 20, respectively, based on coding exon numbering. However, according to the Human Genome Variation Society’s guidelines, exon numbering should commence from exon 1, inclusive of non-coding exons (www.hgvs.org/mutnomen/refseq.html#exinnr) [16]. It was discovered that five out of seven cases (71.4%) were associated with GCLS, a rate slightly exceeding the previously reported 49.1% in EBV-GC [14]. Tumor-infiltrating lymphocytes (TILs ≥ 27.5%) were present in 57.1% of cases in this study, a figure similar to the previously reported 50.0% of intratumoral TILs (≥ 27.5%) [14]. Given the small sample size and retrospective observation, the association between TILs and clinical outcomes should be considered hypothetical in nature and needs to be validated in larger samples and prospective studies. Among the seven patients analyzed, one individual (14.3%) succumbed after a survival period of only six months and did not exhibit GCLS. The remaining five patients (71.4%) with GCLS survived, with four of them being disease-free for 7–30 months at follow-up, and one patient reported no specific discomfort at a 13-month follow-up but did not undergo re-examination. Consequently, the study suggests that GCLS is linked to a more favorable prognosis. This aligns with prior findings indicating that GCLS has a positive prognosis, likely due to the predominance of CD8-positive cytotoxic T cells within stromal lymphocytes, which maintain tumor-specific cytotoxic T lymphocyte activity and provide anti-tumor immune responses [5, 18]. Hisao Matsunou et al. documented two cases of EBV-associated GCLS with extensive liver metastases that responded significantly to anticancer drugs, potentially because the non-connective tissue stroma of GCLS facilitates the entry of these drugs into TCs [5]. Additionally, lymphocyte infiltration is a characteristic pathological feature of EBV-GC. Hence, if this histopathological pattern is observed clinically, such as under endoscopy or microscopy, the patient should be evaluated for EBV infection [11]. Within this study, three out of seven cases (42.9%) were identified as diffuse type based on the Lauren classification, a proportion that aligns with the previously reported 51% for diffuse type EBV-GC [12]. Additionally, Koriyama et al. reported that EBV-GC was linked to a poor prognosis in intestinal-type cancer, whereas diffuse-type EBV-GC exhibited a more favorable prognosis even in the absence of GCLS [18]. Within this study, PD-L1 (TPS) positivity was observed in six out of seven cases (85.7%), which surpasses the previously reported 49.1% PD-L1 (TPS) positivity in EBV-GC by Seo et al. [14]. This variance could be ascribed to the employment of different detection antibodies. Hiroki Tanabe et al. documented that PD-L1 expression in TC for the same group of GC cases was 42.9% (3/7) and 85.7% (6/7) when utilizing E1L3N and SP263 antibodies, respectively [3]. In this study, PD-L1 SP263 was the antibody employed, whereas Seo et al.’s report did not specify the antibody used. Thus, the potential impact of different detection antibodies cannot be excluded. Moreover, Akihito Kawazoe et al. indicated that PD-L1 expression in TC was more prevalent in EBV-positive metastatic gastric cancer (MGC) compared to EBV-negative MGC (21% vs. 4%) [19]. Following the phase II KEYNOTE-059 trial, the FDA has approved pembrolizumab for MGC patients exhibiting PD-L1 expression ≥ 1% in TC or IC, as determined by 22C3 IHC [19]. Consequently, EBV-positive MGC patients may have a higher likelihood of benefiting from immune checkpoint inhibitors (ICI) treatment due to the increased frequency of PD-L1 expression in comparison to EBV-negative MGC patients. Given the small sample size, these observations should be considered as hypothetical in nature and require validation in larger sample sizes and prospective studies. Additionally, within this study, one patient (14.3%) with negative PD-L1 expression succumbed after six months of follow-up, resulting in a survival period of only six months. The remaining six patients (85.7%) with positive PD-L1 expression all survived, with five being disease-free for 7–30 months by the end of the follow-up period, while one patient was followed up for 13 months without re-examination and experienced no specific discomfort. Therefore, the observation in this study that PD-L1 expression is associated with better prognosis should be considered as hypothetical rather than conclusive evidence.Consistent with previous reports, the expression of PD-L1 on tumor cells (TC) and immune cells (IC) correlates with better clinical outcomes of anti-PD-1/PD-L1 antibodies in several malignancies [19]. It should be noted that none of the seven patients in this study received immunotherapy (ICI), making it impossible to directly assess the relationship between PD-L1 expression and immune treatment efficacy. These observations provide valuable references for future related research. In this study, the most prevalent gene mutation observed in EBV-GC was the PIK3CA mutation (42.8%). Boger et al. noted that 5% of GC and 32% of EBV-GC harbored PIK3CA mutations (P < 0.001) [20], a rate consistent with the PIK3CA mutation frequency in EBV-GC identified in this study. The PI3K/AKT/mTOR pathway often experiences various molecular aberrations in human cancers, including PIK3CA mutations, which are frequently present in differentiated cancers [21]. Mutant PIK3CA facilitates the proliferation and invasion of human cancer cells [17]. Preclinical models and early clinical data indicate that PIK3CA mutations may predict responsiveness to PI3K/AKT/mTOR inhibitors across multiple tumor types [21]. Moreover, PIK3CA mutations contribute to resistance against HER2-targeted therapy in breast cancer. Thus, mutant PIK3CA necessitates further investigation as a potential therapeutic target [17]. However, due to the limited sample size of this study, the observation of PIK3CA mutation and clinical or lymphatic vascular infiltration correlation is mainly used to generate hypotheses, and its clinical significance still needs to be verified in larger sample size and prospective studies. Boger et al. also reported that the PIK3CA mutation rate in EBV-GC is significantly higher compared to EBV-negative GC [20]. Consequently, with the increasing prevalence of NGS methods for detecting gene mutations, targeted therapies for PIK3CA mutations are anticipated to undergo high-priority testing in EBV-positive MGC. In this study, a common gene mutation observed in EBV-GC was the ARID1A mutation (42.8%), aligning with the previously reported ARID1A mutation rate of 47–55% in EBV-associated GC [22]. Zang et al. indicated that ARID1A mutations co-occurred with PIK3CA mutations [23]. Functional studies have shown that ARID1A has tumor-suppressive properties. Thus, somatic inactivation of ARID1A could represent a critical oncogenic event in a subset of GC. Given that PI3K inhibitors are presently in clinical trials as potential treatments for GC, it would be pertinent to assess whether the tumor response to these trials is affected by the genomic status of ARID1A [23]. A RAD50 mutation rate of 14.3% in EBV-GC was also identified in this study. High-frequency mutations in HR genes, including RAD50, were reported by Hiroshi Ichikawa et al. HR-deficient ovarian and breast cancers are known to exhibit high sensitivity to platinum-based drugs and poly (ADP-ribose) polymerase inhibitors (PARP inhibitors). Currently, platinum-based chemotherapy is the primary treatment for MGC [2]. Therefore, employing NGS to evaluate defective HR could potentially optimize patient selection for platinum-based chemotherapy in EBV-positive MGC (Fig. 6). EBV-GC subjected to IHC analysis using a PD-L1-specific antibody (SP263) to determine its expression on TC and IC. In EBV-GC, both the cell membranes of TC(A and B) and IC(C and D) were positively stained by the SP263 antibody In this investigation, mutation rates of the tumor suppressor genes PTEN and SMAD4 in EBV-GC were found to be 14.3%. Although targeted treatment strategies for PTEN and SMAD4 mutations remain undeveloped and necessitate further study, the present findings may aid in the future development of gene therapies for EBV-GC. A single case of EBV-GC (14.3%) in this investigation exhibited a high tumor mutational burden (TMB-H, defined as TMB ≥ 10 mut/Mb). The FDA has sanctioned the use of pembrolizumab for treating adult and pediatric patients with unresectable or metastatic solid tumors with high tumor mutational burden (TMB-H, defined as TMB ≥ 10 mut/Mb) that have progressed following previous treatments and have no satisfactory alternative treatment options [24]. Therefore, TMB testing is advocated to facilitate the utilization of ICI in EBV-positive MGC. Notably, the patient’s significantly elevated tumor mutational burden (TMB) of 137.21 Muts/Mb may stem from technical limitations of the sequencing platform or analytical methods, while also reflecting biological characteristics such as Epstein-Barr virus (EBV) infection or genomic instability. Additionally, clinical factors like age and smoking history, along with potential homologous recombination deficiency (HRD) status in the tumor, could influence TMB levels. The identification of TMB-H may be associated with tumor-specific genetic mutations, such as PTEN mutations that promote genomic instability and increase mutation burden. Elevated TMB typically indicates enhanced tumor immunogenicity and may correlate with immune checkpoint inhibitor (ICI) efficacy, providing valuable insights for clinical immunotherapy strategies. In this study, no mutations in TP53, HER2 (also referred to as ERBB2), or EGFR genes were identified, and no MSI was detected, implying that TP53, HER2, EGFR mutations, and D-MMR are not driver genes in EBV-GC. This finding is consistent with earlier reports indicating that TP53 mutations are exceedingly rare in EBV-GC but occur at a rate of 71% in CIN-type GC [22]. It also concurs with Akihito Kawazoe et al.’s findings of no HER2 mutations in 14 cases of EBV-GC [19], indicating that HER-2 targeted therapy is uncommon for EBV-GC. In 2014, the TCGA cohort categorized heterogeneous GC into four molecular subtypes, with MSI tumors and EBV-GC classified under different subtypes of GC [2]. Furthermore, the lack of MSI in EBV-GC in this study is in agreement with this classification, suggesting a potential reduction in MSI testing for EBV-GC. Additionally, the high concordance between IHC and NGS results in this study, such as EBV, MSI, and HER2 detection, underscores the reliability of these testing methods. Clinicians can select either method for related examinations, thereby avoiding redundant tests. Conclusion In summary, the distinctive pathological characteristics of EBV-GC play a significant role in its diagnosis and therapeutic approaches. The elevated expression of PD-L1 and the substantial infiltration of CD8-positive T lymphocytes in EBV-GC imply that this subtype could be amenable to ICI therapy. Additionally, the common occurrence of PIK3CA mutations in EBV-GC may serve as a predictor for sensitivity to PI3K/AKT/mTOR inhibitors. Acknowledgements The authors would like to thank all the reviewers who participated in the review and thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript. We would like to thank Professor Liu Yueping from the Fourth Hospital of Hebei Medical University for his guidance and support. Abbreviations Epstein-Barr virus-associated gastric cancer Next-generation sequencing The Cancer Genome Atlas Microsatellite instability Chromosomal instability Genomically stable Tumor-infiltrating lymphocytes Programmed death-ligand 1 Author contributions Writing–original draft: L W and S L. Writing & editing: L W, S L, L Z, AY L, Y L, JJ W. AY L and S L prepared all figures. All the authors have read & approved the final manuscript. Funding This study was supported by Medical Research Union Found for High-quality health development of Guizhou Province (grant No.2024GZYXKYJJXM0029), Health Commission of Guizhou Province (grant No.gzwjkj2020-1-175), Hospital fund of Affiliated Hospital of Zunyi Medical University [grant No.Yuan Zi(2017)14 Hao], Zunyi Science and Technology Program [grant No. ZunShiKeHe HZ Zi(2024)194 Hao]. Data availability All the data regarding the findings are available within the manuscript. Declarations Ethics approval and consent to participate Due to the retrospective nature of this study, the ethics committee of the hospital waived the informed consent of the patients and confirmed compliance with the Declaration of Helsinki and the confidentiality of the patient data. Consent for publication Written informed consent was obtained from the patient for publication of the study and any accompanying images. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Li Wu and Shuai Luo have contributed equally to this work. References Associated Data Data Availability Statement All the data regarding the findings are available within the manuscript.